Advancing therapeutic development through research and development of innovative assay (test) designs and chemical library screening methods. Learn more.
NCATS researchers lead a collaborative team to design an innovative coincidence-reporter approach to find potential treatments for Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurological diseases.
Find out more about the ADST program, its goals, and its progress to date.
Access state-of-the-art expertise, tools and technologies for assay development and high-throughput screening.
Learn how to collaborate with the ADST program to develop an assay or screen.
Explore the details behind current ADST program projects.
Work with ADST
Find out more and contact Manju Swaroop to get started.
A collaboration involving a patient advocacy group, pharmaceutical companies, academic researchers and ADST program experts culminated in an innovative advance in drug discovery technology, enabling the team to identify a potential new drug target for one of the most common forms of an inherited neurological disorder called Charcot-Marie-Tooth disease. See more ADST in action.
3-D Tissue Bioprinting Program
A Specialized Platform for Innovative Research Exploration
Assay Development and Screening Technology
Assay Guidance Manual
Biomedical Data Translator
Bridging Interventional Development Gaps
Clinical and Translational Science Awards Program
CTSA Program Community Engagement
Discovering New Therapeutic Uses for Existing Molecules
Early Translation Branch
Functional Genomics Lab
Genetic and Rare Diseases Information Center
Matrix Combination Screening
NCATS' Role in the NIH HEAL InitiativeSM
NCATS Toolkit for Patient-Focused Therapy Development
NIH Common Fund Programs
Pfizer's Centers for Therapeutic Innovation
Rare Diseases Registry Program
Rare Diseases Clinical Research Network
Small Business Innovation Research & Small Business Technology Transfer
Therapeutics for Rare and Neglected Diseases
Tissue Chip for Drug Screening
Toxicology in the 21st Century